Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists

Molecular Pharmacology

Volumn 72, Issue 2, 2007, Pages 380-386

  Ma, Jian Nong ^a   Schiffer, Hans H ^a   Knapp, Anne E ^a   Wang, Jean ^a   Wong, Kenneth K ^a   Currier, Erika A ^a   Owens, Michelle ^a   Nash, Norman R ^a   Gardell, Luis R ^a   Brann, Mark R ^a   Olsson, Roger ^a   Burstein, Ethan S ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DILTIAZEM; DILTIAZEM DERIVATIVE; GHRELIN; GHRELIN RECEPTOR; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CALCIUM MOBILIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; GROWTH HORMONE RELEASE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; CALCIUM; CALCIUM CHANNELS, L-TYPE; DILTIAZEM; GROWTH HORMONE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MICE; NIH 3T3 CELLS; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 34547142774     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.034298     Document Type: Article

References (43)

1. Amer A and Maher TJ (2005) Nasal administration of the calcium channel blocker diltiazem decreases food intake and attenuates weight gain in rats. Pharmacol Biochem Behav 82:379-387.
2. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, and Kasuga M (2003) Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52:947-952.
3. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, Malan D, Baj G, Granata R, Broglio F, et al. (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029-1037.
4. Bedendi I, Alloatti G, Marcantoni A, Malan D, Catapano F, Ghe C, Deghenghi R, Ghigo E, and Muccioli G (2003) Cardiac effects of ghrelin and its endogenous derivatives des-octanoyl ghrelin and des-Gln14-ghrelin. Eur J Pharmacol 476:87-95.
5. Benso A, Broglio F, Marafetti L, Lucatello B, Seardo MA, Granata R, Martina V, Papotti M, Muccioli G, and Ghigo E (2004) Ghrelin and synthetic growth hormone secretagogues are cardioactive molecules with identities and differences. Semin Vasc Med 2:107-114.
6. Bowers CY, Momany FA, Reynolds GA, and Hong A (1984) On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 114:1537-1545.
7. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, et al. (2005) Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 315:1278-1287.
8. Burstein ES, Ott TR, Feddock M, Ma JN, Fuhs S, Wong S, Schiffer HH, Brann MR, and Nash NR (2006) Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors. Br J Pharmacol 147:73-82.
9. Cao JM, Ong H, and Chen C (2006) Effects of ghrelin and synthetic GH secretagogues on the cardiovascular system. Trends Endocrinol Metab 17:13-18.
10. Chaffman M and Brogden RN (1985) Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs 29:387-454.
11. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, and Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714-1719.
12. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, and Purnell JQ (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623-1630.
13. de Beaurepaire R and Freed WJ (1989) Behavioral effects of diltiazem injected into the paraventricular nucleus of the hypothalamus. Pharmacol Biochem Behav 33:507-510.
14. Floyd DM, Kimball SD, Krapcho J, Das J, Turk CF, Moquin RV, Lago MW, Duff KJ, Lee VG, White RE, et al. (1992) Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones. J Med Chem 35:756-772.
15. Glossmann H and Striessnig J (1990) Molecular properties of calcium channels. Rev Physiol Biochem Pharmacol 114:1-105.
16. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, and Korbonits M (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988.
17. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, Smith RG, Van der Ploeg LH, and Howard AD (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23-29.
18. Holst B, Brandt E, Bach A, Heding A, and Schwartz TW (2005) Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 19:2400-2411.
19. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, et al. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974-977.
20. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660.
21. Lussier BT, Moor BC, French MB, and Kraicer J (1988) Release of growth hormone from purified somatotrophs: effects of the calcium channel antagonists diltiazem and nifedipine on release induced by growth hormone-releasing factor. Can J Physiol Pharmacol 66:1373-1380.
22. McGraw BF, Walker SD, Hemberger JA, Gitomer SL, and Nakama M(1982) Clinical experience with diltiazem in Japan. Pharmacotherapy 2:156-161.
23. Molden E, Christensen H, and Sund RB (2000) Extensive metabolism of diltiazem and P-glycoprotein-mediated efflux of desacetyl-diltiazem (M1) by rat jejunum in vitro. Drug Metab Dispos 28:107-109.
24. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K (2001a) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280:R1483- R1487.
25. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K (2001b) Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 86:5854-5859.
26. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H, Hirota Y, Ishida H, Mori H, et al. (2001c) Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104:1430-1435.
27. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, and Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194-198.
28. Olsson R, Burstein E, and Knapp AE (2006), inventors; ACADIA Pharmaceuticals, Inc., Olsson R, Burstein E, Knapp AE, assignees. Compounds as modulators of ghrelin receptor and uses thereof. World patent WO2006079077. 2006 July 27.
29. Rovei V, Gomeni R, Mitchard M, Larribaud J, Blatrix C, Thebault JJ, and Morselli PL (1980) Pharmacokinetics and metabolism of diltiazem in man. Acta Cardiol 35:35-45.
30. Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK, et al. (2007) Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. Mol Pharmacol 71:508-518.
31. Schoemaker H, Hicks PE, and Langer SZ (1987) Calcium channel receptor binding studies for diltiazem and its major metabolites: functional correlation to inhibition of portal vein myogenic activity. J Cardiovasc Pharmacol 9:173-180.
32. Shearman LP, Wang SP, Helmling S, Stribling DS, Mazur P, Ge L, Wang L, Klussmann S, Macintyre DE, Howard AD, et al. (2006) Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147:1517-1526.
33. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, Chan WW, Chaung LY, Judith F, et al. (1993) A nonpeptidyl growth hormone secretagogue. Science 260:1640-1643.
34. Sugawara Y, Ohashi M, Nakamura S, Usuki S, Suzuki T, Ito Y, Kume T, Harigaya S, Nakao A, Gaino M, et al. (1988) Metabolism of diltiazem. I. Structures of new acidic and basic metabolites in rat, dog and man. J Pharmacobiodyn 11:211-223.
35. Sugihara J, Sugawara Y, Ando H, Harigaya S, Etoh A, and Kohno K (1984) Studies on the metabolism of diltiazem in man. J Pharmacobiodyn 7:24-32.
36. Takeo S, Tanonaka K, Iwai T, Motegi K, and Hirota Y (2004) Preservation of mitochondrial function during ischemia as a possible mechanism for cardioprotection of diltiazem against ischemia/reperfusion injury. Biochem Pharmacol 67:565-574.
37. Tschöp M, Smiley DL, and Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407:908-913.
38. Uchida Y (1976) Effect of diltiazem, a new anti-Ca agent, on left ventricular function in patients with and without angina pectoris. A study using ultrasonic analogue conversion system. Jpn Heart J 17:599-610.
39. van der Lely AJ, Tschöp M, Heiman ML, and Ghigo E (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: 426-457.
40. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, and Bloom SR (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992.
41. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, and Iga T (2000) Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 292:1118-1126.
42. Zelis RF and Kinney EL (1982) The pharmacokinetics of diltiazem in healthy American men. Am J Cardiol 49:529-532.
43. 3H]TA-3090, a selective benzothiazepine-type calcium channel receptor antagonist: in vitro characterization. J Pharmacol Exp Ther 253:461-465.